Kabi Makes Progress With Denosumab, Phase III Due To Complete
Sandoz Emerged Earlier This With US, EU Filings, US Lawsuit Followed
Fresenius Kabi has welcomed “another testimonial of our efforts to expand our biosimilar portfolio,” with an update for its FKS518 biosimilar denosumab candidate.
